Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Almirall looks to crowdsource new skin health treatments

Launches open innovation platform AlmirallShare

Almirall Spain

Spanish pharma company Almirall has set up an online open innovation platform through which it hopes to find skin health solutions.

Focusing on speeding up the development of new treatments for skin conditions, Almirall is looking to dermatology researchers around the world to post their solutions to challenges posted in sharedinnovation.almirall.com.

The site is underpinned by crowdsourcing technology company Innocentive, whose clients also include AstraZeneca and Boehringer Ingelheim, and current research calls cover preclinical models and high throughput systems for topical drug delivery

Chief scientific officer Dr Bhushan Hardas said: “Our R&D strategy is based on three important aspects: Science, innovation, and partnerships. We are convinced that there are plenty of breakthrough ideas and innovation outside our walls.

“With this in mind, we have created AlmirallShare, our open innovation platform, to help us identify and progress innovative solutions for skin health.”

The Barcelona-headquartered company is looking to work with scientists from universities, public or private research institutions, hospitals, and biotechnology companies.

Maribel Crespo, AlmirallShare leader, said: “AlmirallShare is about shared innovation. With this platform, we want to share our passion for science with experts worldwide to start a journey where cooperation will result in better solutions for skin health. We want to help move science forward.”

Almirall’s first call for research proposals concerns skin pathology in diseases such as psoriasis, atopic dermatitis, acne and rosacea. After proposals are submitted, Almirall said its team would review them and then suggest the best way for the selected proposals to progress.

19th September 2017

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...
Personalised medicine AI
How early-stage clinical research is facilitating the new wave of personalised medicines
By Jorg Taubel...
patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...